Bank of New York Mellon Corp Has $26.09 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of New York Mellon Corp grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,521,166 shares of the biotechnology company’s stock after acquiring an additional 147,748 shares during the period. Bank of New York Mellon Corp owned 0.64% of ADMA Biologics worth $26,088,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Hollencrest Capital Management bought a new stake in ADMA Biologics in the third quarter worth $30,000. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth about $31,000. National Bank of Canada FI bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $35,000. GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Up 0.7 %

Shares of NASDAQ:ADMA opened at $17.02 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock’s 50-day moving average is $16.66 and its 200-day moving average is $17.96. The company has a market cap of $4.02 billion, a P/E ratio of 60.79 and a beta of 0.60. ADMA Biologics, Inc. has a 52-week low of $5.88 and a 52-week high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.